^
    2d
    MDR-ENDPlus: A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis (clinicaltrials.gov)
    P3, N=294, Not yet recruiting, Seoul National University Hospital
    New P3 trial
    |
    CD4 (CD4 Molecule)
    |
    delpazolid (LCB01-0371) • rifampicin
    8d
    Complexed rifampicin with iron mitigates doxorubicin-induced nephrotoxicity. (PubMed, BMC Pharmacol Toxicol)
    In conclusion, we propose the iron-rifampicin complex as a potential candidate for nephroprotection against doxorubicin-induced nephrotoxicity, subject to further validation.
    Journal
    |
    CAT (Catalase)
    |
    doxorubicin hydrochloride • rifampicin
    10d
    RIFACute: Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections (clinicaltrials.gov)
    P3, N=235, Recruiting, Centre Hospitalier Universitaire de Nice | Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> May 2028 | Trial primary completion date: Jul 2027 --> May 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    rifampicin
    10d
    RICHH: Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria (clinicaltrials.gov)
    P2, N=60, Recruiting, Children's Hospital of Philadelphia | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial primary completion date
    |
    rifampicin
    15d
    RIFREE: Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis (clinicaltrials.gov)
    P3, N=422, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jan 2031 --> Jun 2031 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jul 2030 --> Dec 2030
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Head-to-Head
    |
    rifampicin
    29d
    Drug Interaction and Food Effect Study of CS0159 (clinicaltrials.gov)
    P1, N=32, Completed, Cascade Pharmaceuticals, Inc | Trial primary completion date: Feb 2027 --> Mar 2026 | Not yet recruiting --> Completed | Trial completion date: Feb 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    itraconazole • rifampicin
    1m
    Bcl-2 as a Double-edged Sword for the Treatment of Multiple Sclerosis: A Systematic Review. (PubMed, CNS Neurol Disord Drug Targets)
    While modulating Bcl-2 pathways can be effective in MS, future research should aim to provide greater clarification and to design precision-based drugs capable of neuroprotective effects.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IFNB1 (Interferon Beta 1) • LEP (Leptin)
    |
    sirolimus • rifampicin
    1m
    Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease. (PubMed, J Dermatol)
    Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). From Year 1-5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI- patients. The absence of observed TB risk in guselkumab-treated patients suggests IL-23 inhibitors may be better treatment options than TNFi in high-risk patients, including those in TB-endemic regions.
    Journal
    |
    IL23A (Interleukin 23 Subunit Alpha)
    |
    rifampicin
    1m
    QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    |
    Nubeqa (darolutamide) • itraconazole • MHB088C • rifampicin
    1m
    Role of pregnane X receptor in the upregulation of human aldehyde oxidase gene expression. (PubMed, Biochem Pharmacol)
    Treatment of LS180 human colon adenocarcinoma cells, a commonly used human PXR (hPXR) experimental model, with a hPXR agonist (rifampicin, T0901317, SR12813, ritonavir, or paclitaxel) increased AOX1 mRNA expression by 5.2-, 10.2-, 4.7-, 2.2-, and 6.5-fold, respectively, and increased a prototypic hPXR target gene (CYP3A4 mRNA) expression by 9.5-, 13.5-, 7.2-, 3.4-, and 18.0-fold, respectively...It was abolished by actinomycin D, indicating the mRNA increase occurred by a transcriptional mechanism...Control analysis indicated that PCN increased mouse PXR-regulated Cyp3a11 mRNA and Cyp3a-mediated enzyme activity. Overall, our novel data provide evidence for a role of PXR in AOX1 gene expression.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • UGT1A3 (UDP Glucuronosyltransferase Family 1 Member A3)
    |
    paclitaxel • dactinomycin • rifampicin • ritonavir
    1m
    A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial
    |
    rifampicin
    1m
    Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis (clinicaltrials.gov)
    P1, N=32, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed
    Trial completion
    |
    rifampicin